# EDGAR Filing Document

**Accession Number:** 0001782107
**File Stem:** 0001213900-25-120144
**Filing Date:** 2025-12
**Character Count:** 9927
**Document Hash:** 4efab9fe059b9b6a2d717be172a605c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-120144.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001213900-25-120144

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251205

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Onconetix, Inc.
- **CENTRAL INDEX KEY:** 0001782107
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41294
- **FILM NUMBER:** 251562632

**BUSINESS ADDRESS:**
- **STREET 1:** 201 E. FIFTH STREET
- **STREET 2:** SUITE 1900
- **CITY:** CINCINNATI
- **STATE:** OH
- **ZIP:** 45202
- **BUSINESS PHONE:** 513-620-4101

**MAIL ADDRESS:**
- **STREET 1:** 201 E. FIFTH STREET
- **STREET 2:** SUITE 1900
- **CITY:** CINCINNATI
- **STATE:** OH
- **ZIP:** 45202

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Blue Water Biotech, Inc.
- **DATE OF NAME CHANGE:** 20230424

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Blue Water Vaccines Inc.
- **DATE OF NAME CHANGE:** 20190710

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): December 5, 2025**

---

| |
|:---|
| **Onconetix, Inc.** |
| **(Exact name of registrant as specified in its charter)** |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41294** | **83-2262816** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **201 E. Fifth Street, Suite 1900**<br> **Cincinnati, Ohio** | **45202** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (513) 620-4101**

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| Common Stock, par value $0.00001 per share | ONCO | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On December 5, 2025, the Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Onconetix, Inc. (the "Company") held a meeting to review and approve certain executive compensation matters.

At the meeting, the Committee approved a bonus of $45,000 for Karina Fedasz in recognition of her service as the Company's Interim Chief Executive Officer during the year 2025. This bonus is to be paid in January 2026.

Additionally, the Committee approved an increase in Ms. Fedasz's base compensation relating to her services as Interim Chief Executive Officer by $5,000 per month, effective January 1, 2026.

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On December 5, 2025, the Company held its 2025 annual meeting of stockholders (the "Annual Meeting"). The matters voted on at the Annual Meeting were:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) the re-election of Thomas Meier and election of Sarah Romano (the "Director Nominees") to
serve as Class I directors on the Board for a three-year term that expires at the 2028 Annual Meeting of Stockholders, or until their
successors are elected and qualified (the "Director Election Proposal");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) the approval, in accordance with Nasdaq Listing Rule 5635, the issuance of up to 4,424,080 shares of the
Company's Common Stock, par value $0.00001 par value ("Common Stock") subject to adjustment, upon conversion of the
Company's Series D Preferred Stock, par value $0.00001 per share ("Series D Preferred Stock") and up to 4,362,827 shares
of Common Stock, subject to adjustment, upon the exercise of certain warrants (the "Series D Warrants") issued to certain
investors in a private placement transactions which closed on September 22, 2025 (the "Series D PIPE Proposal");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) the approval, in accordance with Nasdaq Listing Rule 5635, the issuance of up to 2,025,223 shares of the
Company's Common Stock, subject to adjustment, upon conversion of the Company's Series E Preferred Stock, par value $0.00001
per share ("Series E Preferred Stock") and up to 2,025,223 shares of Common Stock, subject to adjustment, upon the exercise
of certain warrants (the "Series E Warrants") issued to certain investors in a private placement transactions which closed
on October 1, 2025 (the "Series E PIPE Proposal");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) the ratification of the appointment by the Board of MaloneBailey, LLP ("MaloneBailey") as
the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 (the "Auditor Ratification
Proposal"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) the approval of the adjournment of the Annual Meeting if necessary or appropriate, to solicit additional
proxies if there are insufficient votes at the time of the Annual Meeting to approve any one or more of the foregoing proposals (the "Adjournment
Proposal").

At the Annual Meeting, all of the matters voted on were approved, based upon an aggregate of 1,555,010 shares of Common Stock outstanding as of October 21, 2025, the record date for the Annual Meeting. The final voting results were as follows:

1. Director Election Proposal

The votes were cast for this matter as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Nominees** | **Votes For** | **Votes For** | **Votes Withheld** | **Votes Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
| Thomas Meier |  | 323739 |  | 4959 |  | 325419 |
| Sarah Romano |  | 320886 |  | 7812 |  | 325419 |

---

2. The Series D PIPE Proposal.

The votes were cast for this matter as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes For** | **Votes Against** | **Votes Against** | **Abstentions** | **Abstentions** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 316346 |  | 12288 |  | 64 |  | 325419 |

---

3. The Series E PIPE Proposal.

The votes were cast for this matter as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes For** | **Votes Against** | **Votes Against** | **Abstentions** | **Abstentions** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 316344 |  | 12290 |  | 64 |  | 325419 |

---

4. The Auditor Ratification Proposal.

The votes were cast for this matter as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes For** | **Votes Against** | **Votes Against** | **Abstentions** | **Abstentions** |
|  | 588242 |  | 63447 |  | 2428 |

---

5. The Adjournment Proposal.

The votes were cast for this matter as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes For** | **Votes Against** | **Votes Against** | **Abstentions** | **Abstentions** |
|  | 579157 |  | 78873 |  | 1087 |

---

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Exhibits</u>

The following exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K:

<u>Exhibit No.</u> <u>Description</u> <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Onconetix, Inc.** | **Onconetix, Inc.** |
| December 10, 2025 | By: | */s/ Karina M. Fedasz* |
|  | Name: | Karina M. Fedasz |
|  | Title: | Interim Chief Executive Officer and Interim Chief Financial Officer |

---